Want to join the conversation?
$BMY said its sales for Eliquis were $602MM in 4Q15, which more than doubled from 4Q14. Eliquis is the number one NOAC (novel anticoagulant) in new-to-brand patient share in cardiology across 12 markets around the world. The company continues to see strong demand trends from key markets such as the US, Germany and Japan.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.